EXONEUROGENESIS Trademark

Trademark Overview

On Tuesday, January 14, 2020, a trademark application was filed for EXONEUROGENESIS with the United States Patent and Trademark Office. The USPTO has given the EXONEUROGENESIS trademark a serial number of 88757965. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 8, 2022. This trademark is owned by Cygnal Therapeutics, Inc.. The EXONEUROGENESIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals; research and development in the field of computational biology, bioinformatics, genomics, biotechnology and pharmaceuticals; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology and pharmaceuticals; pharmaceutical preparations for the treatment of cancer and immune system related diseases
exoneurogenesis

General Information

Serial Number88757965
Word MarkEXONEUROGENESIS
Filing DateTuesday, January 14, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 8, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 10, 2020

Trademark Statements

Goods and Servicesscientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals; research and development in the field of computational biology, bioinformatics, genomics, biotechnology and pharmaceuticals; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology and pharmaceuticals; pharmaceutical preparations for the treatment of cancer and immune system related diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateNOT AVAILABLE
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCygnal Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameCygnal Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Monday, August 8, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 8, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, January 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 4, 2022SOU EXTENSION 2 GRANTED
Tuesday, January 4, 2022SOU EXTENSION 2 FILED
Tuesday, January 4, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, July 3, 2021SOU EXTENSION 1 GRANTED
Saturday, July 3, 2021SOU EXTENSION 1 FILED
Saturday, July 3, 2021SOU TEAS EXTENSION RECEIVED
Friday, March 26, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, March 26, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, March 26, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 5, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 10, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 10, 2020PUBLISHED FOR OPPOSITION
Wednesday, October 21, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 2, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 1, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 1, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 29, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 1, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 1, 2020NON-FINAL ACTION E-MAILED
Wednesday, April 1, 2020NON-FINAL ACTION WRITTEN
Wednesday, April 1, 2020ASSIGNED TO EXAMINER
Wednesday, February 12, 2020PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Monday, February 10, 2020ASSIGNED TO LIE
Wednesday, February 5, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, January 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

exoneurogenesis research development field biotechnology pharmaceuticals biology genomics scientific computational bioinformatics